Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

被引:93
作者
Druker, BJ [1 ]
机构
[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA
关键词
Bcr-Abl; tyrosine kinase; inhibitor; CML; STI571;
D O I
10.1038/sj.onc.1206081
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
[No abstract available]
引用
收藏
页码:8541 / 8546
页数:6
相关论文
共 59 条
[1]  
ANAFI M, 1993, BLOOD, V82, P3524
[2]  
Beran M, 1998, CLIN CANCER RES, V4, P1661
[3]   TYROSINE PROTEIN-KINASE INHIBITION AND CANCER [J].
BOUTIN, JA .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY, 1994, 26 (10-11) :1203-1226
[4]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[5]   Bcr-Abl inhibition as a modality of CML therapeutics [J].
Buchdunger, E ;
Matter, A ;
Druker, BJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18
[6]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
[7]  
Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6
[8]   PROTEIN-TYROSINE KINASE INHIBITION - MECHANISM-BASED DISCOVERY OF ANTITUMOR AGENTS [J].
CHANG, CJ ;
GEAHLEN, RL .
JOURNAL OF NATURAL PRODUCTS, 1992, 55 (11) :1529-1560
[9]   Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [J].
Corbin, AS ;
Buchdunger, E ;
Pascal, F ;
Druker, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32214-32219
[10]  
Corbin AS, 2000, BLOOD, V96, p470A